news
Parkinson’s disease market to hit $3.2 billion by 2021
25 February 2016 | By Victoria White
GBI Research states that Parkinson’s disease market growth will occur despite the patent expiries of several key products during the forecast period...
List view / Grid view
Parkinson's disease
news
Acorda to acquire Biotie; gains rights to tozadenant
19 January 2016 | By Victoria White
In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease...
news
Parkinson’s disease treatment pipeline holds significant potential, says GBI Research
12 January 2016 | By Victoria White
An analyst at GBI Research states that the pipeline for the disease is highly active, consisting of 365 programmes across all stages of development, and a diverse range of molecular targets...
news
Nilotinib improved cognition and motor skills in Parkinson’s trial
19 October 2015 | By Victoria White
Nilotinib, a treatment for leukaemia, improved cognition, motor skills and non-motor function in patients with Parkinson's disease in a Phase I clinical trial...
news
Biotie announces start of tozadenant Phase 3 study in Parkinson’s disease
21 July 2015 | By Victoria White
A Phase 3 study of tozadenant in patients with Parkinson's disease experiencing levodopa related end-of-dose "wearing-off" has started...
news
Recent drug approvals will boost Parkinson’s disease therapeutics market
2 July 2015 | By Victoria White
The Parkinson’s disease treatment market value across eight major countries will reach $4.7 billion by 2022, says GlobalData...
news
NTCELL Phase I/IIa study meets endpoints
15 June 2015 | By Victoria White
A Phase I/IIa study of NTCELL, an regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease, has met its endpoints...
news
FDA lifts clinical hold on ND0612H and ND0612L for the treatment of Parkinson’s disease
8 May 2015 | By
The FDA has lifted the clinical hold on clinical studies of ND0612H and ND0612L, NeuroDerm's product candidates for the treatment of Parkinson’s disease...
news
NeuroDerm to announce updated topline results of Phase II Study of ND0612L for the treatment of Parkinson’s disease
1 April 2015 | By Victoria White
NeuroDerm has announced that updated results from the Phase II Study of ND0612L will be presented at the American Academy of Neurology 67th Annual Meeting...
news
Biotie provides portfolio update on tozadenant
20 February 2015 | By Biotie
Biotie has announced further detail on its clinical development plan for tozadenant, an adenosine A2a antagonist in development for Parkinson's disease (PD)...
news
nLife Therapeutics receives USD 350,000 from The Michael J. Fox Foundation for Parkinson’s Research
23 September 2014 | By nLife Therapeutics
The funding will help characterize the mechanism of action of nLife’s lead compound NLF-PD-1233 in a Parkinson disease model and find a proper dose to engage clinical development...
news
Actavis confirms Generic Neupro® Patent challenge
26 August 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr...
news
FDA approves expanded label for AZILECT® for treatment across all stages of Parkinson’s Disease
9 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced the U.S. Food and Drug Administration has expanded the indication for AZILECT® (rasagiline tablets)...
news
Lundbeck part of major advances in the understanding of Parkinson’s disease
20 May 2014 | By Lundbeck
H. Lundbeck A/S is involved in new research on Parkinson’s disease, which may be the first step towards a new and significantly improved treatment of the debilitating and devastating disease...
news
Lundbeck receives grant from The Michael J. Fox Foundation for biological markers identification in Parkinson’s disease
6 May 2014 | By H. Lundbeck A/S
H. Lundbeck A/S has once again received support and recognition for its research on Parkinson’s disease through a grant from The Michael J. Fox Foundation for Parkinson’s Research...
